RxDoctor Payments DataLook up a doctor →

Mazen Hanna, MD

Cardiovascular Disease · Cleveland, OHNPI 1033128731

Payments from drug & device makers

$1,612,008in general payments, 2019–2025

Across 208 payments — averaging $7750.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$659K
  • AstraZeneca$408K
  • Alnylam Pharmaceuticals Inc.$319K
  • American Regent$121K
  • Ionis Pharmaceuticals, Inc.$84K
  • Astrazeneca UK Limited$5K
  • plus $16K from 17 others
$49,450in research payments, 2019–2025

Across 43 payments — averaging $1150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$49K

What the payments were for

  • Consulting fees$114,14555%
  • Speaking & faculty fees$49,15824%
  • Travel & lodging$40,36919%
  • Food & beverage$4,1742%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,612,008 in reported general payments places this provider in the 95th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$59,702
Medicare patients
290
Services billed
642

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis740$18,205,473
VyndaqelTafamidis Meglumine91$1,974,070
JardianceEmpagliflozin203$257,181
EliquisApixaban143$165,477
EntrestoSacubitril/Valsartan117$154,074
FarxigaDapagliflozin Propanediol63$80,753
XareltoRivaroxaban25$32,458
Eplerenone66$5,864
Torsemide147$4,052
Metoprolol Succinate157$2,517
Diflunisal23$2,158
Spironolactone305$1,705
Amiodarone Hcl36$1,592
Digoxin80$1,025
Atorvastatin Calcium82$886

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Vyndaqel, Eliquis$659,223$20,345,020974 claims
Boehringer IngelheimJardiance$125$257,181203 claims
AstraZenecaFarxiga$408,358$80,75363 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →